Related Experiment Video
Updated: Jun 14, 2025
A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
Published on: August 15, 2019
PBMC-engrafted humanized mice models for evaluating immune-related and anticancer drug delivery systems
Yoshie Kametani1,2, Ryoji Ito3, Yoshiyuki Manabe4
1Department of Molecular Life Science, Division of Basic Medical Science, Tokai University School of Medicine, Isehara, Japan.
Abstract:
Immune-related drug delivery systems (DDSs) in humanized mouse models are at the forefront of cancer research and serve as bridges between preclinical studies and clinical applications. These systems offer unique platforms for exploring new therapies and understanding their interactions with human cells and the immune system. Here, we focus on a DDS and a peripheral blood mononuclear cell (PBMC)-engrafted humanized mouse model that we recently developed, and consider some of the key components, challenges, and applications to advance these systems towards better cancer treatment on the basis of a better understanding of the immune response. Our DDS is unique and has a dual function, an anticancer effect and a capacity to fine-tune the immune reaction. The PBL-NOG-hIL-4-Tg mouse system is superior to other available humanized mouse systems for the development of such multifunctional DDSs because it supports the rapid reconstruction of an individual donor's immunity and avoids the onset of graft-versus-host disease.
Insights
Researchers developed a novel drug delivery system (DDS) and a humanized mouse model for advanced cancer research. This dual-function DDS targets cancer and modulates immune responses, improving therapy development.
Area of Science:
- Oncology
- Immunology
- Biomedical Engineering
Background:
- Immune-related drug delivery systems (DDSs) are crucial for bridging preclinical cancer research and clinical applications.
- Humanized mouse models provide platforms for studying drug interactions with human immune systems.
- Understanding immune responses is key to developing effective cancer therapies.
Purpose of the Study:
- To introduce a novel dual-function DDS with anticancer and immune-modulating capabilities.
- To present a peripheral blood mononuclear cell (PBMC)-engrafted humanized mouse model for evaluating multifunctional DDSs.
- To discuss challenges and applications for advancing DDSs in cancer treatment.
Main Methods:
- Development of a unique DDS with dual anticancer and immune-tuning functions.
- Establishment of a PBL-NOG-hIL-4-Tg humanized mouse model for rapid immune reconstruction.
- Evaluation of the DDS and model system for cancer therapy research.
Main Results:
- The developed DDS exhibits both direct anticancer effects and the ability to fine-tune immune reactions.
- The PBL-NOG-hIL-4-Tg mouse model facilitates rapid engraftment of individual donor immunity.
- This model system avoids graft-versus-host disease, enhancing its utility for DDS development.
Conclusions:
- The novel DDS and humanized mouse model represent significant advancements in cancer therapy research.
- This integrated system offers a superior platform for developing multifunctional DDSs.
- Further development holds promise for improved cancer treatment strategies based on immune response modulation.
